Press News

Press News

2014.07.10 tella and Medical Corporation Isokai (Seren Clinic Tokyo) to Begin Joint Clinical Study for the DC Vaccine Vaccell® Using the New Cancer Antigens Survivin Peptides and MAGE-A4 Peptides

tella, Inc. (Head office: Minato-ku, Tokyo; President & Representative Director: Yuichiro Yazaki) has signed a joint research agreement with Medical Corporation Isokai (Address: Minato-ku, Tokyo; President: Tadashi Dobashi). Based on this agreement, tella will begin a clinical study for cancer patients with Seren Clinic Tokyo (Address: Minato-ku, Tokyo; Hospital Director: Masaki Nagaya) for the dendtric cell (DC) vaccine Vaccell® using the new cancer antigens survivin peptides and MAGE-A4 peptides.

The new cancer antigens are based a patented technology which tella holds exclusive rights to use. Survivin peptides have been patented in Japan and Australia and MAGE-A4 peptides have been patented in Japan and the United States. Previous cancer antigen peptides (MHC class I restricted peptides) activated only killer T-cells (Cytotoxic T-cells). But these peptides can also increase the number of cancer-specific killer T-cells by efficiently activating helper T-cells.

Survivin peptides and MAGE-A4 peptides, which will be used for this clinical study, are hybrid long peptides that combine MHC class I and class II restricted peptides, and are covered by the patent. These are next-generation cancer antigen peptides that can stimulate an even more powerful immunological response to cancer. The purpose of this clinical study is to evaluate the safety and efficacy of the DC vaccine Vaccell® pulsed survivin peptides and MAGE-A4 peptides. The goal is to enable the practical use of new cancer antigens as soon as possible.

The Seren Clinic Group (Tokyo, Nagoya, Kobe, Fukuoka) has used the DC vaccine Vaccell® for 3,528 cases (as of June 30, 2014), which is the most among all tella contracted medical institutions. In addition, tella and Seren Clinic Group plan to analyze clinical data for preparing research papers and making presentations at symposiums in order to provide even better treatments for people who have cancer.

tella will continue to promote R&D activities for the practical use of new cancer antigens. The goal is to give the large number of cancer patients more treatment options.